Twist Bioscience Corporation Total Liabilities and Equity
Twist Bioscience Corporation (TWST) had Total Liabilities and Equity of $672.44 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-03
- 2026-06-30: Liabilities and Equity $672.44M.
- 2026-03-31: Liabilities and Equity $676.21M.
- 2025-12-31: Liabilities and Equity $638.09M.
- 2025-09-30: Liabilities and Equity $641.86M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $672.44M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $676.21M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $638.09M 10-Q/A · filed 2026-02-26 |
| 2025-09-30 | $641.86M 10-Q · filed 2026-08-03 |
| 2025-06-30 | $643.61M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $595.62M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $608.58M 10-Q · filed 2025-02-03 |
| 2024-09-30 | $614.32M 10-K · filed 2025-11-17 |
| 2024-06-30 | $638.12M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $702.85M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $732.82M 10-Q · filed 2024-02-02 |
| 2023-09-30 | $776.40M 10-K · filed 2024-11-18 |
| 2023-06-30 | $810.33M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $853.92M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $909.97M 10-Q · filed 2023-02-07 |
| 2022-09-30 | $961.38M 10-K · filed 2023-11-21 |
| 2022-06-30 | $979.66M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.02B 10-Q · filed 2022-05-06 |
| 2021-12-31 | $786.17M 10-Q · filed 2022-02-09 |
| 2021-09-30 | $702.10M 10-K/A · filed 2023-06-05 |
| 2021-06-30 | $725.30M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $677.29M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $699.57M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $398.88M 10-K · filed 2021-11-23 |
| 2020-06-30 | $408.24M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $323.87M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $192.28M 10-Q · filed 2020-02-10 |
| 2019-09-30 | $186.99M 10-K · filed 2020-11-27 |
| 2019-06-30 | $206.81M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $140.17M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $164.45M 10-Q · filed 2019-02-11 |
| 2018-09-30 | $115.79M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |